REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
9.03
-0.23 (-2.48%)
Sep 17, 2025, 4:00 PM EDT - Market closed
REGENXBIO Stock Forecast
Stock Price Forecast
The 8 analysts that cover REGENXBIO stock have a consensus rating of "Strong Buy" and an average price target of $28.5, which forecasts a 215.61% increase in the stock price over the next year. The lowest target is $12 and the highest is $52.
Price Target: $28.5 (+215.61%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for REGENXBIO stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $34 | Strong Buy | Reiterates | $34 | +276.52% | Sep 8, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $52 | Strong Buy | Maintains | $52 | +475.86% | Sep 8, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $34 | Strong Buy | Reiterates | $34 | +276.52% | Aug 19, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $21 → $17 | Buy | Maintains | $21 → $17 | +88.26% | Aug 8, 2025 |
| Barclays | Barclays | Buy Maintains $50 → $37 | Buy | Maintains | $50 → $37 | +309.75% | Aug 8, 2025 |
Financial Forecast
Revenue This Year
252.71M
from 83.33M
Increased by 203.27%
Revenue Next Year
254.18M
from 252.71M
Increased by 0.58%
EPS This Year
-1.71
from -4.59
EPS Next Year
-2.69
from -1.71
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 437.9M | 349.6M | |||
| Avg | 252.7M | 254.2M | |||
| Low | 148.4M | 137.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 425.5% | 38.3% | |||
| Avg | 203.3% | 0.6% | |||
| Low | 78.1% | -45.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.97 | 1.95 | |||
| Avg | -1.71 | -2.69 | |||
| Low | -4.18 | -5.59 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.